Maxim Group analyst Jason Kolbert weighed in Vertex (NASDAQ: VRTX) after VX661/ivacaftor Phase II failed to impress in homozygotes ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE